Status:

WITHDRAWN

Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)

Lead Sponsor:

Emory University

Conditions:

Acute Lymphoblastic Leukemia

Eligibility:

All Genders

Up to 21 years

Phase:

PHASE1

Brief Summary

The goal of this study is to find a safe dose of sirolimus that can be used with a standard dose of L-asparaginase. To find the safe dose, the investigators will give the first patient a very small do...

Detailed Description

Multiple relapsed acute lymphoblastic leukemia (ALL) has a very poor cure rate, and there is no standard of care for treatment of these patients. Therefore, we want to combine two chemotherapy drugs t...

Eligibility Criteria

Inclusion

  • Less than 21 years old.
  • Acute lymphoblastic leukemia.
  • Second or greater bone marrow relapse or 1st relapse and refractory to at least 2 Attempts at re-induction.
  • Life expectancy of at least 8 weeks.
  • Fully recovered from the acute toxic effects of all prior therapy.
  • Appropriate organ function.

Exclusion

  • Patients with a documented history of ≥ grade 3 local or systemic reactions to PEG-asparaginase.
  • Patients with a documented history of anti-E. coli asparaginase antibodies.
  • Patients with a history of ≥ grade 3 pancreatitis.
  • Patients with an active and uncontrolled infection.
  • Patients s/p allogeneic bone marrow transplantation, who are still on immunosuppressants.
  • Pregnant or lactating females. Women of childbearing age will agree to use contraception during the protocol.
  • Patients currently receiving other investigational agents, medications, or supplements with a known anti-leukemic effect.
  • Other concomitant medications that may alter the metabolism of Sirolimus (See section 7.2).
  • Patients who, in the opinion of the investigator, will not be able to comply with safety monitoring requirements of the study.
  • Patients with a history of a documented thrombus from previous asparaginase therapy.

Key Trial Info

Start Date :

June 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2012

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00957320

Start Date

June 1 2009

End Date

August 1 2012

Last Update

December 3 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Children's Healthcare of Atlanta

Atlanta, Georgia, United States, 30322